Plus Therapeutics, Inc. (the Company) announced that the World Health Organization's (WHO) International Non-proprietary Name (INN) Expert Committee has selected the non-proprietary name Rhenium ((186) Re) obisbemeda for the Company's lead investigational targeted radiotherapeutic, formerly known as (186) RNL. Going forward, Plus Therapeutics will use Rhenium ((186) Re) obisbemeda in place of (186) RNL. The assignment of Rhenium ((186) Re) obisbemeda as the recommended INN for (186) RNL is another important milestone in the ongoing development of lead targeted radiotherapeutic as plan to move it towards mid- and late-stage clinical development, including a planned Phase 2 trial in patients with recurrent glioblastoma by the end of 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.24 USD | -0.44% | +3.70% | +27.99% |
05-15 | Transcript : Plus Therapeutics, Inc., Q1 2024 Earnings Call, May 15, 2024 | |
05-09 | Transcript : Plus Therapeutics, Inc. - Special Call |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+27.99% | 9.58M | |
+33.63% | 50.93B | |
-0.09% | 42.12B | |
+49.62% | 42.05B | |
-4.96% | 29.18B | |
+11.18% | 26.02B | |
-21.95% | 18.9B | |
+8.61% | 13.21B | |
+24.73% | 12.17B | |
+28.31% | 12.16B |
- Stock Market
- Equities
- PSTV Stock
- News Plus Therapeutics, Inc.
- Plus Therapeutics, Inc. Announces Selection of Rhenium Obisbemeda as International Non-Proprietary Name for 186RNL